Hematopoietic Stem Cell TransplantationTransplantation, HomologousBone Marrow TransplantationGraft vs Host DiseaseHematopoietic Stem CellsTransplantation ConditioningHematologic NeoplasmsStem Cell TransplantationTransplantation, AutologousTransplantation ChimeraBone MarrowTissue DonorsBone Marrow CellsGraft vs Leukemia EffectWhole-Body IrradiationPeripheral Blood Stem Cell TransplantationBusulfanLeukemiaTreatment OutcomeHistocompatibilityHistocompatibility TestingGraft SurvivalStem CellsRecurrenceMyeloablative AgonistsGraft vs Tumor EffectChimerismRetrospective StudiesHematologic DiseasesLeukemia, Myeloid, AcuteAnemia, AplasticMyelodysplastic SyndromesHematopoiesisCord Blood Stem Cell TransplantationImmunosuppressive AgentsVidarabineRemission InductionHLA AntigensLymphocyte TransfusionHepatic Veno-Occlusive DiseasePrecursor Cell Lymphoblastic Leukemia-LymphomaAllograftsTransplantation, IsogeneicTime FactorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCombined Modality TherapySiblingsLiver TransplantationT-LymphocytesTransplantation ImmunologySurvival RateCytomegalovirus InfectionsSurvival AnalysisAcute DiseaseCyclophosphamideMice, Inbred C57BLHematopoietic Stem Cell MobilizationFlow CytometryAntigens, CD34Lymphocyte DepletionDisease-Free SurvivalSevere Combined ImmunodeficiencyMultiple MyelomaFollow-Up StudiesCell DifferentiationOpportunistic InfectionsCystitisMinor Histocompatibility AntigensLeukemia, MyeloidLeukemic InfiltrationImmunosuppressionAntilymphocyte SerumNeoplasm, ResidualLymphoproliferative DisordersSalvage TherapyKidney TransplantationColony-Forming Units AssayGraft RejectionBone and BonesAntineoplastic Combined Chemotherapy ProtocolsCell LineageCytomegalovirusCells, CulturedImmunocompromised HostPrognosisFatal OutcomeBlood Group IncompatibilityRisk FactorsBronchiolitis ObliteransFetal BloodBone Marrow PurgingGranulocyte Colony-Stimulating FactorCyclosporineCytarabineCell TransplantationMesenchymal Stem Cell TransplantationRadiation ChimeraMelphalanPrimary MyelofibrosisMycoses